Evidence for antibody as a protective correlate for COVID-19 vaccines
2021 · Vaccine · 961 citations
https://doi.org/10.1016/j.vaccine.2021.05.063
P
Peter Dull
Gates Foundation(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
115
Papers
7.3K
Citations
48
h-index
81
i10-index
Peter Dull is an academic researcher from Gates Foundation. The author has contributed to research in topics: Bacterial Infections and Vaccines & Pneumonia and Respiratory Infections & Influenza Virus Research Studies. The author has an h-index of 48, co-authored 98 publications.
Papers by this author
worksTowards a population-based threshold of protection for COVID-19 vaccines
2021 · Vaccine · 181 citations
https://doi.org/10.1016/j.vaccine.2021.12.006
A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
2013 · Drugs · 156 citations
https://doi.org/10.1007/s40265-013-0155-7
Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results
2023 · Nature Medicine · 76 citations
https://doi.org/10.1038/s41591-023-02658-0
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
2014 · International Journal of Infectious Diseases · 23 citations
https://doi.org/10.1016/j.ijid.2014.06.008
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial
2016 · Vaccine · 19 citations
https://doi.org/10.1016/j.vaccine.2016.11.009
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat